1、BetamethasoneCat. No.: HY-13570CAS No.: 378-44-9Molecular Formula: CHFOMolecular Weight: 392.46Target: Glucocorticoid ReceptorPathway: GPCR/G ProteinStorage: 4C, protect from lightSolvent 95% confidence interval: -4.1 to 0.8 mm Hg; diastolic: -0.3 mm Hg; 95% confidence interval: -2.5 to 1.8 mm Hg) 2
2、. Intra-articular corticosteroid injection of 6 mg of betamethasone acetate/betamethasone sodium phosphate at the knee joint was not significantly associated with SAI at the time points tested 3.Clinical indications: Dermatitis; Discoid lupus erythematosus; Eczema; Lichen; Prurigo; PsoriasisToxicity
3、: Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.Product Data Sheet InhibitorsAg
4、onistsScreening Librarieswww.MedChemE1REFERENCES1. Arai, K., et al., Comparative study of the effects of betamethasone butyrate propionate, vitamin D3 derivatives, and cyclosporine on human lymphocyte-proliferation stimulated with a hemolytic streptococci-derived superantigen. Eur J Pharmacol, 2007.
5、 571(2-3): p. 222-30.2. Dalziel, S.R., et al., Blood pressure at 6 years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics, 2004. 114(3): p. e373-7.3. Habib, G., et al., The effect of intra-articular injection of betamethasone acetate/be
6、tamethasone sodium phosphate at the knee joint on the hypothalamic-pituitary-adrenal axis: a case-controlled study. J Investig Med, 2013. 61(7): p. 1104-7.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USAwww.MedChemE2
